Breast cancer in patients after augmentation with implants

Relevance. Currently, there is no definite answer to the question of the cause of breast cancer, since it is a systemic and multifactorial disease. Given that the number of aesthetic operations on the mammary glands using endoprostheses only increases every year, new cases of detection of malignant diseases do not decrease. Some researchers are beginning to speak out about the possible connection of augmentation mammoplasty in the anamnesis with the subsequent occurrence of breast cancer due to inadequate clinical and instrumental examination and ignoring some of its components (for example, the mammographic examination). Introduction. Taking into account the analysis of the literature and the presented clinical examples, the possible reasons for the connection of augmentation mammoplasty in the anamnesis with the subsequent detection of a malignant neoplasm are analyzed. Materials and methods. We analyzed domestic and foreign literature and described two clinical examples with authentic documentation based on the results of the examination and treatment. The article describes in detail the schemes of drug treatment and descriptions of the results of morphological examination of the surgical material. The types and results of surgical treatment with reliable photos are also presented. Results. Given the complexity of the diagnostic stage in patients with breast endoprosthesis in the described clinical examples, family history collected in sufficient detail, cytogenetic studies conducted, we should talk about the likely underdiagnosis during preventive examinations. Conclusion. The multifactorial and systematic nature of such a disease as breast cancer suggests that perhaps an intensive increase in the detectability of the above-mentioned against the background of previously performed aesthetic surgery would be the simplest solution to the problem. In this category of patients, anamnesis should be collected in more detail and carefully, and the entire complex of clinical and instrumental examinations, including mammography, magnetic resonance and ultrasound examinations, should be performed in order to fully diagnose and develop further patient management tactics.

Download Full-text

Analysis of Key Radiographic Characteristics of Early Invasive Breast Cancer, Stages T₁ₐ₋bN₀M₀ and DCIS

Journal of oncology: diagnostic radiology and radiotherapy ◽

10.37174/2587-7593-2021-4-1-9-19 ◽

2021 ◽

Vol 4 (1) ◽

pp. 9-19

Author(s):

G. S. Alieva ◽

G. P. Korzhenkova ◽

I. V. Kolyadina

Keyword(s):

Breast Cancer ◽

Ductal Carcinoma In Situ ◽

Invasive Breast Cancer ◽

Carcinoma In Situ ◽

World Literature ◽

Ductal Carcinoma ◽

Early Stage ◽

Malignant Neoplasm ◽

Morphological Examination

Relevance: The systematization of radiological signs of microcarcinomas will increase the frequency of detection of the disease at an early stage and maximize the effectiveness of breast cancer treatment.Purpose: To assess the key radiological characteristics of early forms of breast cancer (invasive tumors up to 1.0 cm and ductal carcinoma in situ).Material and methods: The key radiological characteristics were studied in 110 patients with verified early forms of breast cancer: ductal carcinoma in situ (DCIS), invasive breast cancer up to 1 cm in size according to the morphological examination of the surgical material in the absence of signs of regional and distant metastasis — stage p T₁ₐ₋bN₀M₀.Results: The main radiological signs detected in mammography (MG) in early breast cancer were the nodular mass without microcalcifications — in 26 cases (23.9 %), the nodule and microcalcifications — in 35 cases (32.1 %), in 27 patients (24.8 %) — microcalcifications without a tumor node. In addition, in 17 cases (15.6 %) there was a violation of the architectonics or focal asymmetry, and in 4 patients (3.7 %) no signs of a malignant process were revealed at all with MG. The revealed changes in the breast in most patients (83 cases, 76.1 %) were interpreted as BIRADS 5, which indicates an extremely high probability of the presence of a malignant neoplasm. In 9 cases (8.3 %) after mammography, the diagnosis was interpreted as BIRADS 4, in 16 (14.7 %) cases the category BIRADS 0 was assigned, which required additional examination methods, and only in 1 patient (0.9 %) the revealed changes were interpreted as benign.Conclusions: Mammography performed in 92 patients (84.4 %), based on the assessment of radiological signs, to establish the BIRADS 4/5 category, which served as the basis for performing a biopsy and verifying the diagnosis. However, in 15 % there were diagnostic difficulties in interpreting the data, which confirms the data of the world literature on the complexity of the differential diagnosis of microcarcinomas.

Download Full-text

Construction of mammographic findings simulators to study the interference of silicone implants in the diagnosis of breast cancer

MedNEXT Journal of Medical and Health Sciences ◽

10.54448/mdnt21624 ◽

2021 ◽

Vol 2 (6) ◽

Author(s):

Lucila Franz Bezerra ◽

Lenita Franz Bezerra ◽

Kaiser Kruger ◽

Everton Granemann Souza ◽

Chiara Das Dores do Nascimento

Keyword(s):

Breast Cancer ◽

Malignant Neoplasm ◽

Density Variation ◽

Silicone Implants ◽

Augmentation Mammoplasty ◽

Dimensionless Unit ◽

Pvc Film ◽

The Individual ◽

Two Stages ◽

Made In

Introduction: Breast cancer is the most prevalent malignant neoplasm among women, presenting itself, in 99% of cases, in females. Augmentation mammoplasty is the most performed aesthetic surgical intervention in the world. Objective: This study aims to improve the search for biomaterials compatible with mammographic findings suggestive of malignancy, to further study the interference of silicone implants in mammography exams. Methods: To make the simulators of mammographic findings, a bibliographic study of possible biomaterials that presented compatibility with the breast tissue and with possible neoplastic findings was carried out. The validation process of the simulators made in this work was carried out in two stages. Results: The result found was a density variation between 2.54 and 2.57 (dimensionless unit). For the second plate, the individual optical density of each material was analyzed. The results found for fiberglass ranged between 1.95 and 2.63. For chicken eggshells between 0.59 and 0.80. For the glycerin suppository, values between 1.43 and 2.29 were found. And for plastic PVC film 1.78 to 2.53. Conclusion: Given the above, it is observed that the first plate as a whole is compatible with mammographic studies. However, on the second plate, when the materials were analyzed separately, it was observed that fiberglass and plastic PVC film were the closest to compatibility with the commercial phantom, being compatible materials to simulate breast neoplasms in possible further studies.

Download Full-text

Proteomic Analysis of Zeb1 Interactome in Breast Carcinoma Cells

Molecules ◽

10.3390/molecules26113143 ◽

2021 ◽

Vol 26 (11) ◽

pp. 3143

Author(s):

Sergey E. Parfenyev ◽

Sergey V. Shabelnikov ◽

Danila Y. Pozdnyakov ◽

Olga O. Gnedina ◽

Leonid S. Adonin ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Epithelial To Mesenchymal Transition ◽

Critical Role ◽

Malignant Neoplasm ◽

Malignant Neoplasms ◽

Breast Cancer Patients ◽

Survival Prognosis ◽

Mesenchymal Transition ◽

Wide Range

Breast cancer is the most frequently diagnosed malignant neoplasm and the second leading cause of cancer death among women. Epithelial-to-mesenchymal Transition (EMT) plays a critical role in the organism development, providing cell migration and tissue formation. However, its erroneous activation in malignancies can serve as the basis for the dissemination of cancer cells and metastasis. The Zeb1 transcription factor, which regulates the EMT activation, has been shown to play an essential role in malignant transformation. This factor is involved in many signaling pathways that influence a wide range of cellular functions via interacting with many proteins that affect its transcriptional functions. Importantly, the interactome of Zeb1 depends on the cellular context. Here, using the inducible expression of Zeb1 in epithelial breast cancer cells, we identified a substantial list of novel potential Zeb1 interaction partners, including proteins involved in the formation of malignant neoplasms, such as ATP-dependent RNA helicase DDX17and a component of the NURD repressor complex, CTBP2. We confirmed the presence of the selected interactors by immunoblotting with specific antibodies. Further, we demonstrated that co-expression of Zeb1 and CTBP2 in breast cancer patients correlated with the poor survival prognosis, thus signifying the functionality of the Zeb1–CTBP2 interaction.

Download Full-text

Cosmetics and Cancer: Adverse Event Reports Submitted to the Food and Drug Administration

JNCI Cancer Spectrum ◽

10.1093/jncics/pky012 ◽

2018 ◽

Vol 2 (2) ◽

Cited By ~ 2

Author(s):

Saya L Jacob ◽

Erika Cornell ◽

Michael Kwa ◽

William E Funk ◽

Shuai Xu

Keyword(s):

Breast Cancer ◽

Ovarian Cancer ◽

Adverse Event ◽

Drug Administration ◽

Media Coverage ◽

Food And Drug Administration ◽

Adverse Event Reporting System ◽

Malignant Neoplasm ◽

Cosmetic Products ◽

Specific Product

Abstract There have been numerous controversies surrounding cosmetic products and increased cancer risk. Such controversies include associations between parabens and breast cancer, hair dyes and hematologic malignancies, and talc powders and ovarian cancer. Despite the prominent media coverage and numerous scientific investigations, the majority of these associations currently lack conclusive evidence. In 2016, the US Food and Drug Administration (FDA) made publically available all adverse event reports in Center for Food Safety and Applied Nutrition’s Adverse Event Reporting System (CAERS), which includes complaints related to cosmetic products. We mined CAERS for cancer-related reports attributed to cosmetics. Between 2004 and 2017, cancer-related reports caused by cosmetics represented 41% of all adverse events related to cosmetics. This yielded 4427 individual reports of cancer related to a cosmetic product. Of these reports, the FDA redacted the specific product names in 95% of cancer-related reports under the Freedom of Information Act exemptions, most likely due to ongoing legal proceedings. For redacted reports, ovarian cancer reports dominated (n = 3992, 90%), followed by mesothelioma (n = 92, 2%) and malignant neoplasm unspecified (n = 46, 1%). For nonredacted reports, or those reports whose product names were not withheld (n = 218), 70% were related to ovarian cancer attributed to talc powders, followed by skin cancer (11%) and breast cancer (5%) attributed to topical moisturizers. Currently, CAERS is of limited utility, with the available data having been subjected to significant reporter bias and a lack of supportive information such as demographic data, medical history, or concomitant product use. Although the system has promise for safeguarding public health, the future utility of the database requires broader reporting participation and more complete reporting, paired with parallel investments in regulatory science and improved molecular methods.

Download Full-text

Surgical treatment of a cancerous uterus

Journal of obstetrics and women s diseases ◽

10.17816/jowd119889-901 ◽

2020 ◽

Vol 11 (9) ◽

pp. 889-901

Author(s):

A. P. Gubarev

Keyword(s):

Breast Cancer ◽

Surgical Treatment ◽

Uterine Cancer ◽

Malignant Neoplasm ◽

Surgical Methods

Surgical treatment of any malignant neoplasm can make sense only when the possibility of relapses is taken into account and everything that can be achieved by art to eliminate them or prevent them. This is a principle that modern surgery persistently applies in the development of surgical methods for removing neoplasms, no matter in whatever area it develops. The greatest development in this direction has recently undergone surgery for breast cancer. At present, there can no longer be any question of removing, in addition to the neoplasm, only enlarged and infiltrated or suspicious glands, it is not enough even to remove healthy glands: in the form in which the details of this operation were developed by prof. Kocher), Watson Cheyne) and others, the removal of all tissue in the armpit and in the circumference of the musculi pectoralis majoris is a condition, the need for which can hardly be discussed. In a word, the removal of those tissues in which relapses develop more easily and most often is a rule adopted by modern surgery. Therefore, the principles that guide modern gynecology in the surgical treatment of uterine cancer seem to be completely random and poorly understood: in many cases, not the tissues that are most dangerous in the sense of relapse are removed, namely those in which relapses appear only as a rarity, or an exception and which more than others resist him.

Download Full-text

Augmentation mammoplasty: effect on diagnosis of breast cancer

Journal of Plastic Reconstructive & Aesthetic Surgery ◽

10.1016/j.bjps.2007.06.035 ◽

2008 ◽

Vol 61 (2) ◽

pp. 124-129 ◽

Cited By ~ 19

Author(s):

S.A. McIntosh ◽

K. Horgan

Keyword(s):

Breast Cancer ◽

Augmentation Mammoplasty

Download Full-text

Breast cancer as second malignant neoplasm after acute myeloid leukemia: A rare occurrence

Clinical Cancer Investigation Journal ◽

10.4103/2278-0513.186105 ◽

2016 ◽

Vol 5 (4) ◽

pp. 333 ◽

Cited By ~ 1

Author(s):

SmithaCarol Saldanha ◽

Govind Babu ◽

MallekavuSuresh Babu ◽

LakshmaiahChinnagiriyappa Kuntegowdanahalli ◽

LakkavalliKrishnappa Rajeev ◽

...

Keyword(s):

Breast Cancer ◽

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Malignant Neoplasm ◽

Rare Occurrence ◽

Second Malignant Neoplasm ◽

Acute Myeloid

Download Full-text

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06109-7 ◽

2021 ◽

Author(s):

Andrew Wardley ◽

Javier Cortes ◽

Louise Provencher ◽

Kathy Miller ◽

A. Jo Chien ◽

...

Keyword(s):

Breast Cancer ◽

Androgen Receptor ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Eastern Cooperative Oncology Group ◽

Malignant Neoplasm ◽

Efficacy And Safety ◽

Open Label ◽

Group Status

Abstract Purpose Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor receptor 2-positive (HER2+) breast cancers. In vitro, AR inhibitors enhance antitumor activity of trastuzumab, an anti-HER2 antibody, in trastuzumab-resistant HER2+ cell lines. This open-label, single-arm, phase II study evaluated the efficacy and safety of enzalutamide, an AR-signaling inhibitor, in patients with advanced HER2+ AR+ breast cancer previously treated with trastuzumab. Methods Eligible patients had measurable or non-measurable evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Eastern Cooperative Oncology Group status ≤ 1, no history of brain metastases, and previously received ≥ 1 anti-HER2 regimen for advanced disease. Patients received 160 mg oral enzalutamide daily and 6 mg/kg intravenous trastuzumab every 21 days until disease progression or unacceptable toxicity. Primary end point was clinical benefit rate at 24 weeks (CBR24); secondary end points included progression-free survival (PFS) and safety. Results Overall, 103 women were enrolled [median age 60 years (range 34–83)]; 62% had received ≥ 3 lines of prior anti-HER2 therapy. CBR24, comprising patients with confirmed partial responses (5%) and durable stable disease at 24 weeks (19%), was 24% in the efficacy evaluable set (n = 89). CBR24 did not seem related to AR-expression levels or hormone receptor status. Median PFS was 3.4 months (95% confidence interval 2.0–3.8). Overall, 97 (94%) patients experienced treatment-emergent adverse events (TEAEs), with fatigue most common (34%). Dyspnea (4%) and malignant neoplasm progression (3%) were the only TEAEs grade ≥ 3 reported in ≥ 3 patients. 22 patients (21%) reported serious TEAEs. Four patients (4%) experienced fatal, non-drug-related TEAEs. Conclusions Enzalutamide plus trastuzumab was well tolerated, and a subset of patients in this heavily pretreated population had durable disease control. Determination of biomarkers is needed to identify patients most likely to benefit from this combination. ClinicalTrials.gov number NCT02091960

Download Full-text